-
Je něco špatně v tomto záznamu ?
Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting
T. Etrych, P. Chytil, T. Mrkvan, M. Šírová, B. Říhová, K. Ulbrich
Jazyk angličtina Země Nizozemsko
Typ dokumentu práce podpořená grantem
NLK
ScienceDirect (archiv)
od 1993-01-01 do 2009-12-31
- MeSH
- akrylamidy aplikace a dávkování farmakokinetika farmakologie chemická syntéza MeSH
- biologický transport MeSH
- buněčné linie MeSH
- doxorubicin aplikace a dávkování farmakokinetika farmakologie chemická syntéza MeSH
- farmaceutická chemie MeSH
- hydrolýza MeSH
- injekce intravenózní MeSH
- koncentrace vodíkových iontů MeSH
- léky s prodlouženým účinkem MeSH
- lymfom farmakoterapie metabolismus patologie MeSH
- molekulová hmotnost MeSH
- myši inbrední C3H MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- nosiče léků MeSH
- protinádorová antibiotika aplikace a dávkování farmakokinetika farmakologie chemická syntéza MeSH
- xenogenní modely - testy protinádorové aktivity MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- práce podpořená grantem MeSH
Synthesis, physicochemical behavior, tumor accumulation and preliminary anticancer activity of a new biodegradable graft copolymer-doxorubicin (DOX) conjugates designed for passive tumor targeting were investigated. In the graft high-molecular-weight conjugates the multivalent N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer was grafted with a similar but semitelechelic HPMA copolymer; both types of polymer chains were bearing doxorubicin attached by hydrazone bonds enabling intracellular pH-controlled drug release. The polymer grafts were attached to the main chain through spacers, degradable enzymatically or reductively, facilitating, after the drug release, intracellular degradation of the graft polymer carrier to short fragments excretable from the organism by glomerular filtration. The graft polymer-DOX conjugate exhibited prolonged blood circulation and enhanced tumor accumulation in tumor-bearing mice indicating the important role of the EPR effect in the anticancer activity. The graft polymer-DOX conjugates showed a significantly higher antitumor activity in vivo than DOX.HCl or the linear polymer conjugate when tested in mice bearing 38C13 B-cell or EL4 T-cell lymphoma, with a significant number of long-term-surviving (LTS) mice with EL4 T-cell lymphoma treated with a single dose 15 mg DOX equiv./kg on day 10.
- 000
- 03698naa 2200625 a 4500
- 001
- bmc11017380
- 003
- CZ-PrNML
- 005
- 20121129101057.0
- 008
- 110629s2008 ne e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Etrych, Tomáš $7 xx0068504
- 245 10
- $a Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting / $c T. Etrych, P. Chytil, T. Mrkvan, M. Šírová, B. Říhová, K. Ulbrich
- 314 __
- $a Institute of Macromolecular Chemistry AS CR, v.v.i., Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic.
- 520 9_
- $a Synthesis, physicochemical behavior, tumor accumulation and preliminary anticancer activity of a new biodegradable graft copolymer-doxorubicin (DOX) conjugates designed for passive tumor targeting were investigated. In the graft high-molecular-weight conjugates the multivalent N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer was grafted with a similar but semitelechelic HPMA copolymer; both types of polymer chains were bearing doxorubicin attached by hydrazone bonds enabling intracellular pH-controlled drug release. The polymer grafts were attached to the main chain through spacers, degradable enzymatically or reductively, facilitating, after the drug release, intracellular degradation of the graft polymer carrier to short fragments excretable from the organism by glomerular filtration. The graft polymer-DOX conjugate exhibited prolonged blood circulation and enhanced tumor accumulation in tumor-bearing mice indicating the important role of the EPR effect in the anticancer activity. The graft polymer-DOX conjugates showed a significantly higher antitumor activity in vivo than DOX.HCl or the linear polymer conjugate when tested in mice bearing 38C13 B-cell or EL4 T-cell lymphoma, with a significant number of long-term-surviving (LTS) mice with EL4 T-cell lymphoma treated with a single dose 15 mg DOX equiv./kg on day 10.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a akrylamidy $x aplikace a dávkování $x farmakokinetika $x farmakologie $x chemická syntéza $7 D000178
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorová antibiotika $x aplikace a dávkování $x farmakokinetika $x farmakologie $x chemická syntéza $7 D000903
- 650 _2
- $a biologický transport $7 D001692
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a farmaceutická chemie $7 D002626
- 650 _2
- $a léky s prodlouženým účinkem $7 D003692
- 650 _2
- $a doxorubicin $x aplikace a dávkování $x farmakokinetika $x farmakologie $x chemická syntéza $7 D004317
- 650 _2
- $a nosiče léků $7 D004337
- 650 _2
- $a koncentrace vodíkových iontů $7 D006863
- 650 _2
- $a hydrolýza $7 D006868
- 650 _2
- $a injekce intravenózní $7 D007275
- 650 _2
- $a lymfom $x farmakoterapie $x metabolismus $x patologie $7 D008223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C3H $7 D008809
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a molekulová hmotnost $7 D008970
- 650 _2
- $a xenogenní modely - testy protinádorové aktivity $7 D023041
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1#
- $a Chytil, Petr. $7 _AN032430
- 700 1_
- $a Mrkvan, Tomáš $7 xx0062385
- 700 1_
- $a Šírová, Milada $7 xx0127158
- 700 1_
- $a Říhová, Blanka, $d 1942- $7 jo20000073671
- 700 1_
- $a Ulbrich, Karel, $d 1947- $7 jo2004259877
- 773 0_
- $t Journal of Controlled Release $w MED00002621 $g Roč. 132, č. 3 (2008), s. 184-192
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110720113703 $b ABA008
- 991 __
- $a 20121129101125 $b ABA008
- 999 __
- $a ok $b bmc $g 864254 $s 727193
- BAS __
- $a 3
- BMC __
- $a 2008 $x MED00002621 $b 132 $c 3 $d 184-192 $m Journal of controlled release $n J Controlled Release
- LZP __
- $a 2011-3B09/BBjvme